Yuan, Karen

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

Liu, P. C., Dixit, V., Mayo, M., Dey, J., Yuan, K., Karnik, R., Walther, D., Shi, Y., Sharma, K., Rong, H., et al. (2021) · Blood

Protein Degradation and InhibitorsCytokine Signaling Pathways and Interactions

Cited by 26

CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers

Kwiatkowski, N., Liang, T., Sha, Z., Collier, P. N., Yang, A., Sathappa, M., Paul, A., Su, L., Zheng, X., Aversa, R., et al. (2025) · Cell Chemical Biology

Protein Degradation and InhibitorsAdvanced Breast Cancer Therapies

Cited by 23